EVVIVAX is a spin-off of
Takis Biotech, a company developing a number of Innovative Immunotherapies
EVVIVAX is at the forefront of nucleic-acid based therapies, process development, industrial scale production and clinical trial execution
EVVIVAX stems from new, European platform technologies, aims to offer novel therapeutic avenues to pet cancer patients, with the strong translational potential to complement current human Immune-Oncology approaches in the next future.